Showing 8 of 28 recruiting trials for “obsolete-inherited-predisposition-to-essential-thrombocythemia”
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecruitingNCT06516406 ↗
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
Ruxolitinib in Thrombocythemia and Polycythemia Vera
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
👨⚕️ Angela Fleischman, MD, PhD, Chao Family Comprehensive Cancer Center📍 2 sites📅 Started Jan 2022View details ↗
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia
👨⚕️ Lei Zhang, MD, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Jan 2020View details ↗
RecruitingNCT02897297 ↗
Myeloproliferative Neoplastic Diseases Observatory From Brest
← PreviousPage 2 of 2
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →